Recent phase 3 trials compared the effect of DPD and an injectable ESA in anemic (Hb: 8.0–11.5 g/dl) dialyzed and non-dialyzed patients with CKD (67, 68). The gene discussed is GSTM1; the disease is chronic kidney disease.